Why Jennifer Doudna is one of Fast Company’s 10 most innovative people of the last 10 years
Doudna codeveloped the revolutionary gene-editing technology known as CRISPR-Cas9. Now it’s leading to ...
"Reengineering Life: The Next Frontiers in Science" is Fareed Zakaria GPS's special report on CNN profiling Nobel Laureate and Innovative Genomics Institute founder Jennifer Doudna and the development, rise, ...
If the first CRISPR decade was marked by a mad dash to evolve, engineer, and mine the bacterial universe for more and better genome-editing enzymes, so far the second seems ...
New advancements in artificial intelligence have the capacity to deliver major breakthroughs in cancer therapy.
AI-powered protein design company Profluent used AI to make an open-source gene editor called OpenCRISPR-1.
OpenCRISPR-1 ...
Late blight is an old foe of humans. This disease catalysed the devastating Irish potato famine that began in 1845.
It is caused by a fungus-like pathogen, which quickly kills ...
For stretched public health budgets, high-tech treatments are hard to afford but some pre-emptive measures can prove good value.
As hay fever season arrives, once again, for allergy and asthma ...
Much as ChatGPT generates poetry, a new A.I. system devises blueprints for microscopic mechanisms that can edit your DNA.
Generative A.I. technologies can write poetry and computer programs or create images of teddy ...
Funding propels company’s proprietary platform consisting of Generative AI models and large-scale datasets purpose-built for designing and validating novel proteins, opening new frontiers in therapeutics and industrial applications
...
Expanding medical therapies based on Crispr gene-editing globally is “unrealistic” and the sector needs heavy investment to make the technology, which could transform treatment of diseases, accessible to all, ...
Around 10 million. That’s the number of lives forecasters believe we will lose each year by 2050 as bacteria develop defenses against the drugs we use to fight infections.
Tackling antibiotic resistance, though, ...
In his January 20, 2024 TEDxBerkeley Talk, Dr. Benjamin Oakes delves into the profound potential of CRISPR technology and its ability to transform healthcare.
Dr. Oakes is co-founder and ...
The Beacon for CRISPR Cures aims to create a roadmap for rapidly developing genome-editing therapies.
The story of CRISPR in medicine so far has been one of remarkable speed. It ...
Crispr recently marked a major milestone in medicine. But it's not time for a victory lap—the race is just beginning.
By Jennifer Doudna, CRISPR pioneer and Nobel Laureate at the ...
Editing DNA with the same ease as spell-checking a Word document is a scientific holy grail. It would allow debilitating and deadly genetic diseases to not only be treated, ...
In a landmark decision, the Food and Drug Administration Friday approved the first gene-editing treatment to alleviate human illness.
The FDA approved two gene therapies for anyone 12 and older ...
The Food and Drug Administration’s approval on Friday of two groundbreaking gene therapy treatments for sickle cell disease has brought a rare moment of hope and celebration to people with the ...
The gene-editing revolution is jumping from the lab to the marketplace.
The U.S. has approved the world’s first medicine employing Crispr technology, a Nobel Prize-winning discovery that promised a powerful new tool ...
In a major advance, the Food and Drug Administration on Friday approved two gene therapies that target sickle cell disease, one of which is the first commercially available treatment in the United States ...
It was only 11 years ago that scientists Jennifer Doudna and Emmanuelle Charpentier first described a new way to edit genes, called CRISPR, in a scientific paper. The discovery is so game-changing ...
When Victoria Gray was still a baby, she started howling so inconsolably during a bath that she was rushed to the emergency room. The diagnosis was sickle-cell disease, a ...
It usually takes time for scientific discoveries in the lab to make their way to the market.
The groundbreaking gene-editing technology known as Crispr, which acts like a molecular pair ...
History just happened.
For the first time, a regulator has cleared a treatment using CRISPR, the gene-editing technology, for patients. The regulator is the United Kingdom’s Medicines and Healthcare products ...
Technology is all about solving big thorny problems. Yet one of the hardest things about solving hard problems is knowing where to focus our efforts. There are so many urgent ...
Over the ages, scientists have devised medicines to successfully treat thousands of illnesses, but eliminating rare and deadly maladies altogether is a holy grail. Treatments for inherited conditions like ...
Over the ages, scientists have devised medicines to successfully treat thousands of illnesses, but eliminating rare and deadly maladies altogether is a holy grail. Treatments for inherited conditions like ...
I SEE YOU, reader. You drink the probiotic seltzer, with its gut-improving bacteria, and the fiber-filled prebiotic. You regularly consume eclectic fermented foods and burly amounts of kale to ...
Benjamin Oakes' Scribe Therapeutics is developing specialized Crispr proteins to tackle a wide range of diseases–and it’s garnered deals with Big Pharma potentially worth over $4 billion.
In 2013, Benjamin ...
Scientists are engineering microbes to make healthier compounds. They hope they’ll help treat disease and save the planet.
Microbes have been on my mind this week. These tiny organisms are ...
Hype springs eternal in medicine, but lately the horizon of new possibility seems almost blindingly bright. “I’ve been running my research lab for almost 30 years,” says Jennifer Doudna, ...
CRISPR pioneer Jennifer Doudna's company Scribe Therapeutics inked a major deal with Prevail Therapeutics potentially worth $1.5 billion to create genetic medicines for neurological and neuromuscular diseases. Scribe CEO ...
Scribe Therapeutics found another partner, this time with Prevail Therapeutics, a subsidiary of Eli Lilly, in a $75 million upfront deal for neuromuscular and neurological diseases.
Unlike Scribe’s ex vivo ...
Collaboration combines Scribe Therapeutics’ novel CRISPR by Design™ approach with Prevail Therapeutics’ deep expertise in developing genetic medicines for neurological disorders towards specified genetic targets
Scribe to receive ...
Deep in the bellies of cows are tiny microbes that ferment grass and hay, breaking it down into fatty acids that serve as bovine energy—and into planet-warming methane gas. ...
We sat down with some of the most curious minds in life sciences and healthcare and invited them to share their thoughts on their careers, the future of health ...
The parents of a 2-year-old girl write that their daughter “could die within the next year” because a genetic mutation is causing her heart to fail.
“Time is quickly running ...
A guide to contemporary doomsday scenarios — from the threats you know about to the ones you never think of.
And here we are at the crux of our existential ...
From the philosophers whose moral imagination pushes the boundaries of what is possible to the activists making the world a better and healthier place on the ground, from the ...
Sanofi has teamed up with Scribe Therapeutics to write the next chapter in its natural killer (NK) cell therapy story, paying $25 million upfront and committing to $1 billion ...
Scribe Therapeutics Inc., a molecular engineering company pioneering a CRISPR by Design™ platform for genetic medicine, today announced a strategic collaboration with Sanofi for the use of Scribe’s CRISPR ...